CCL2 and breast neoplasm: Cancer development and progression could be decreased by 6-shogaol via inhibiting the production of inflammatory mediator chemokine (C-C motif) ligand 2 (CCL2), derived from breast tumor-associated dendritic cells (TADCs) [128].